A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies — Stella
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
United States
Dana-Farber Cancer Institute, Boston, Massachusetts
START MidWest PI Sharma, Grand Rapids, Michigan
Sarah Cannon Research Institute PI McKean Nasville, TN, USA, Nashville, Tennessee
MD Anderson PI Champiat, Houston, Texas
Start San Antonio PI Rasco, San Antonio, Texas
NEXT PI Spira, Fairfax, Virginia
Canada
Princess Margaret Cancer Center PI Spreafico, Toronto
France
Gustave Roussy Cancer Campus Grand Paris- (Institut de Cancerologie Gustave-Roussy) - PI Ronan, Villejuif
Spain
Hospital Universitario Vall d'Hebron PI Garralda Cabanas, Barcelona
NEXT Quiron-Barcelona - PI Saavedra Santa Gadea, Barcelona
START Madrid - CIOCC. Grupo Hospital de Madrid (HM) - Centro Integral Oncologico Clara Campal (CIOCC) - Calvo Aller, Madrid